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INTRODUCTION
Gitelman's syndrome (GS) is an autosomal recessive inher-
ited disorder first described by Gitelman et al. in 1966 (1).
It is, also known as a ‘hypocalciuric variant' of Bartter's syn-
drome (BS) or as  ‘familial hypokalemia-hypomagnesemia', a
primary renal tubular disorder characterized by chronic hy-
pokalemia, hypomagnesemia and metabolic alkalosis of renal
origin, hyperreninemia, hypocalciuria not related to hypocal-
cemia or renal failure, and a normal glomerular filtration rate
(GFR) (1-5).
Colussi et al. (6) studied the distal nephron NaCl reabsorp-
tion in adult patients with GS by analyzing the paired effects
of the two diuretics furosemide (FUR) and hydrochloro-
thiazide (HCT), and showed that the functional activity of
the renal thiazide-sensitive Na
+-Cl
- cotransporter (but not of
the furosemide-sensitive carrier) is deficient in patients with
GS, in keeping with the recently described genetic link be-
tween the syndrome and a wide variety of nonconservative
mutations of the gene encoding the protein (7, 8).
Recently we diagnosed a patient as GS by evaluating the
distal nephron function with two diuretics FUR and HCT.
It is suggested that the dynamic studies with diuretic admin-
istration may be of diagnostic help in GS.
CASE REPORT
A 16 yr-old girl was referred to Chonnam National Univer-
sity Hospital for evaluation of hypokalemia. She sometimes
had noticed fatigue and muscle weakness during exercise.
She was found to be hypokalemic when she visited a private
clinic for evaluation of occasional abdominal pain. At the
admission to our hospital, she was normotensive (120/80
mmHg) with normal renal function (BUN 12 mg/dL, serum
creatinine 0.8 mg/dL). She showed serum potassium levels
of 2.7 mEq/L (3.5-5.1 mEq/L), serum magnesium levels of
1.4 mg/dL (1.6-2.1 mg/dL) and urinary calcium levels of
9.0 mg/day (50-250 mg/day). The plasma renin activity was
elevated to 63.8 ng/mL/hr (1.3-3.9 ng/mL/hr), albeit plasma
aldosterone concentration was 19.2 pg/mL (4-31 pg/mL).
She had metabolic alkalosis (arterial blood pH 7.46, PaCO2
46 mmHg, and HCO3
- 32 mEq/L) and hyperreninemia, sug-
gesting extracellular fluid volume contraction, but the urinary
Na
+ and/or Cl
- excretion was not reduced (268 mEq/day and
283 mEq/day, respectively; normal value, 100-260 mEq/day
for both of them). The plasma aldosterone level was not ele-
vated as expected for the degree of hyperreninemia, possibly
due to an inhibitory effect of hypokalemia (9). She showed
normal serum calcium and phosphorus levels, and the uri-
nary albumin excretion and ultrasonography findings of the
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Attenuated Renal Excretion in Response to Thiazide Diuretics in
Gitelman's Syndrome
: A Case Report
Gitelman's syndrome is a variant of Bartter's syndrome characterized by hypocal-
ciuria and hypomagnesemia. The administration of thiazide diuretics may induce
a subnormal increase of urinary Na
+ and Cl
- excretion in patients with Gitelman's
syndrome, consistent with the hypothesis that less Na
+ and Cl
- than normal is reab-
sorbed by the thiazide-inhibitable transporter in Gitelman's syndrome. Specific
mutations of NaCl cotransporter, coupled with mutant NaCl cotransporter expres-
sion studies clearly demonstrated that many of the characteristics of individuals
with Gitelman's syndrome are explained by lack of function of NaCl cotransporter.
We recently diagnosed a patient with Gitelman's syndrome by performing the
thiazide and furosemide tests, and it is suggested that the clearance studies by
diuretic administration may be of diagnostic help in Gitelman's syndrome. 
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kidneys were normal. No family history of BS or related dis-
orders was found. Her parents had not noticed fatigue or
muscle weakness. She denied any past medical history or the
medical prescription including diuretics, laxatives, or cathar-
tics. Physical examination showed no abnormality.
All the above mentioned features and exclusion of any sur-
reptitious diuretic intake excluded common causes of renal
K
+ loss and metabolic alkalosis such as primary hyperaldos-
teronism, surreptitious vomiting, and diuretic and/or laxative
abuse and were consistent with the diagnosis of a primary
tubular disorder. The diagnosis of GS rather than classic BS
was favored by patient's age, absence of overt polyuria or the
tendency to dehydration, and the presence of hypocalciuria
and/or hypomagnesemia (1-5).
She was interrupted from any pharmacological therapy for
at least 10 days before the studies and allowed a free-choice
diet. FUR and HCT tests were carried out at least 7 days
apart, and performed by the study protocol described previ-
ously (6). Parameters were calculated as follows: Maximal
free water clearance (CH2O)=(1-Uosm/Posm)×V, Chloride clear-
ance (CCl)=UCl×V/PCl, and Distal fractional chloride reab-
sorption=CH2O/(CH2O+CCl), where V=urinary flow (mL/
min), Uosm=urinary osmolality, and Posm=plasma osmolality.
After FUR administration, the patient showed a marked
increase in chloride clearance (CCl, from 3.05 to 26.71 mL/
min/100 mL Ccr) and decrease in free water clearance (CH2O,
from 9.19 to 3.83 mL/min/100 mL Ccr), although HCT did
not significantly change chloride clearance (CCl, from 1.01
to 1.45 mL/min/100 mL Ccr) and free water clearance (CH2O,
from 2.45 to 2.45 mL/min/100 mL Ccr). On the contrary,
distal fractional chloride reabsorption (CH2O/[CH2O+CCl]) was
significantly decreased by FUR administration (from 75.1
to 12.54 %), whereas HCT ingestion had little effect on this
parameter (from 70.8 to 62.8 %).
HCT test
The patient had lower plasma K
+ levels and similar plasma
Na
+, and Cl
- levels (Table 1) and  ‘basal' excretions of Na
+,
Cl
-, and K+ levels, compared to normal controls published
elsewhere (6) (Table 2). However, after HCT administration
the patient showed a lower increase of both FENa and FECl (Fig.
1, Table 1), and lower  ‘cumulative' and  ‘net' Na
+ and Cl
-
excretions (Table 2), while the K+ excretion was significantly
lower only for the  ‘cumulative' evaluation.
FUR test
The patient showed normal plasma Na
+ and Cl
- levels,
lower plasma K
+ level (Table 3), and higher  ‘basal' urinary
excretions of Na
+, Cl
-, and K+ levels, compared to normal
pNa (mEq/L) 139 137.3
pCl (mEq/L) 103 103.3
pK (mEq/L) 2.9 4.11
Ccr (mL/min) 92.3 119.8
FENa (bas, %) 0.82 1.2
FECl (bas, %) 1.2 1.96
FEK (bas, %) 14.7 14.8
FENa (max, %) 1.43 2.52
FECl (max, %) 1.25 3.64
FEK (max, %) 11.27 9.7
Patient Control*
Table 1. HCT test results: plasma electrolyte levels, creatinine
clearance, and fractional electrolyte clearance before (bas) and
at its maximal increase over basal levels (max) are shown
FE (bas) is the mean of two pre-HCT clearances;  FE (max) indicates
the difference between maximal excretion at any time (max) after HCT
administration and FE (bas).
*Control data were mean value obtained from reference 6.
UNaV (bas)  mol/min 114.2 122.3
UNaV (cum) mmol/150 min 39.7 69.4
UNaV (net) mmol/150 min 21.4 47.5
UClV (bas)  mol/min 174.2 189.4
UClV (cum) mmol/150 min 43.4 69.1
UClV (net) mmol/150 min 17.8 40.7
UKV (bas)  mol/min 59.3 66.4
UKV (cum) mmol/150 min 7.3 13.8
UKV (net) mmol/150 min 1.13 3.85
Patient Control*
Table 2. HCT test results: quantitative electrolyte excretion
‘Cumulative' electrolyte excretion [UxV (cum)] is total electrolyte excre-
tion from 30 to 180 min after HCT administration; ‘net' electrolyte excre-
tion [UxV (net)] is calculated by subtracting from ‘cumulative'  excre-
tion ‘basal' excretion multiplied by 150 min.
*Control data were mean value obtained from reference 6.
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Fig. 1. HCT-induced mean absolute changes above basal levels
(mean of the two basal clearances) of fractional excretion of sodi-
um at different times after diuretic administration in our patient
(open columns) and controls (closed columns).Renal Excretion to Thiazide in Gitelman's Syndrome 569
controls published elsewhere (6) (Table 4). After FUR admin-
istration, she showed greater increases of FENa and FECl (Fig.
2, Table 3), higher  ‘cumulative' excretions of Na
+ and Cl
-,
and a higer  ‘net' Na
+ excretion, while the K+ excretion was
not different from the controls (Table 4).
DISCUSSION
Classic BS and GS are likely to represent distinct tubular
disorders: specifically a defect of the loop of Henle in the for-
mer and that of the distal tubule in the latter (5), despite com-
mon pathogenetic mechanisms. In both of them, the primary
tubular defect would imply a reduction of NaCl reabsorption
at the involved site, with a secondary increase of NaCl delivery
to the distal nephron sites (mostly the cortical collecting tu-
bule), stimulation of electrogenic Na
+ reabsorption, and K
+
and H
+ hypersecretion at these sites, resulting in hypokalemia
and metabolic alkalosis.
Two members of an electroneutral Na-Cl cotransporter
family predominantly expressed in the kidney (namely, the
‘loop'-type diuretic-sensitive symporter expressed in the
thick ascending limb of Henle's loop and the thiazide-sensi-
tive symporter expressed in the distal convoluted tubule)
have recently been recognized and cloned (7, 8). Indeed, the
administration of thiazide diuretics induced a subnormal
increase of urinary Na
+ and Cl
- excretions in a few patients
with GS studied by different centres (3, 10, 11), an observa-
tion consistent with the hypothesis that less Na
+ and Cl
- than
normal is reabsorbed by the thiazide-inhibitable transporter
in GS.
In our study, the HCT induced blunted natriuresis and
chloruresis as compared with control values, while FUR has
a slightly increased effect. The different effects of the two
diuretics in our patient were not related to any differences
in plasma Na
+ and Cl
- levels (which were normal in GS) or
in GFR: in fact, the electrolyte excretion changes were smaller
in the patients both in absolute terms and in relation to unit
GFR (i.e., in FE values), indicating a blunted diuretic effect
at the single-nephron level. Thus, the different diuretic effects
in GS patients were likely to represent different effects of the
two drugs on the renal tubule itself.
The chloride clearance (CCl) and the distal fractional chlo-
ride reabsorption (CH2O/[CH2O+CCl]) showed abrupt change
after FUR administration, while HCT induced little effect
in our patient. The most likely explanation of our data is that
the decreased diuretic effect of HCT in GS patients was the
expression of reduced NaCl reabsorption via the thiazide-
inhibitable electroneutral Na
+/Cl
- symporter of the distal
convoluted tubule, due to some abnormalities of structure
or expression in the cell membrane of the carrier protein. 
pNa (mEq/L) 139 136.7
pCl (mEq/L) 99 103.4
pK (mEq/L) 2.7 4.03
Ccr (mL/min) 81.6 118.8
FENa (bas, %) 2.31 1.19
FECl (bas, %) 4.21 1.75
FEK (bas, %) 26.63 18.2
FENa (max, %) 28.33 17.8
FECl (max, %) 41.10 24.5
FEK (max, %) 43.7 39.1
Patient Control*
Table 3. FUR test results: plasma electrolyte levels, creatinine
clearance, and fractional electrolyte clearance before (bas) and
at its maximal increase over basal levels (max) are shown
FE (bas) is the mean of three pre-FUR clearances;  FE (max) indi-
cates the difference between maximal excretion at any time (max) after
HCT administration and FE (bas)
*Control data were mean value obtained from reference 6.
UNaV (bas,  mol/min) 202.89 167.7
UNaV (cum, mmol/30 min) 89.79 61.4
UNaV (net, mmol/30 min) 83.70 56.4
UClV (bas,  mol/min) 297.6 189.6
UClV (cum, mmol/30 min) 92.86 65.5
UClV (net, mmol/30 min) 78.4 60.0
UKV (bas,  mol/min) 83.97 73.6
UKV (cum, mmol/30 min) 6.47 6.1
UKV (net, mmol/30 min) 3.95 3.8
Patient Control*
Table 4. FUR test results: quantitative electrolyte excretion
‘Cumulative' electrolyte excretion [UxV (cum)] is total electrolyte excre-
tion from 5 to 35 min after FUR administration; ‘net' electrolyte excretion
[UxV (net)] is calculated by subtracting from ‘cumulative' excretion  ‘basal'
excretion multiplied by 30 min.
*Control data were mean value obtained from reference 6.
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Fig. 2. FUR-induced mean absolute changes above basal levels
(mean of three basal clearances) of fractional excretion of sodium
at different times after diuretic administration in our patient (open
columns) and controls (dark columns).570 C.-H. Yeum, S.-W. Kim, S.-K. Ma, et al.
In conclusion, GS is characterized by blunted diuretic effect
of the thiazide, but not of the loop diuretics. These observa-
tions appear to represent a direct functional ‘in vivo' counter-
part of the recently described link between GS and a series of
genetic mutations of the gene encoding the renal thiazide-
sensitive Na
+-Cl
- cotransporter.
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